Integrating Patient Support Design Into Clinical Development Plan Is Critical to Cell and Gene Therapies
Roshawn Blunt, managing director of 1798, a Fingerpaint company, authored an article for Pharmaceutical Executive on why integrating patient assistance programs for cell and gene therapies into the overall clinical development plan is critical.
“These programs provide drug copayment assistance to commercially insured patients or give free drugs to low-income patients,” she wrote. “While these programs are ubiquitous to pharmaceutical products, they must be modified to support the needs and characteristics of the patient population that may benefit from curative CGTs.”
Read Blunt’s full article in Pharmaceutical Executive.